NEO - NeoGenomics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

NeoGenomics, Inc.

12701 Commonwealth Drive
Suite 9
Fort Myers, FL 33913
United States
239-768-0600
http://www.neogenomics.com

SectorHealthcare
IndustryDiagnostics & Research
Full Time Employees1,500

Key Executives

NameTitlePayExercisedYear Born
Mr. Douglas M. VanOortChairman & CEO1.42MN/A1955
Mr. William Bishop BonelloChief Strategy & Corp. Devel. Officer and Director of Investor Relations512.07kN/A1966
Mr. George A. CardozaPres of Pharma Services Division564.36kN/A1962
Mr. Robert J. ShovlinPres of Clinical Services Division591.14k3.59M1971
Dr. Lawrence M. Weiss M.D.Chief Medical Officer & Chairman of Scientific Advisory Board703.79kN/A1956
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services, which focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Corporate Governance

NeoGenomics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 4. The pillar scores are Audit: 3; Board: 4; Shareholder Rights: 3; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.